While Waiting for Valeant's 10-K, Five Questions for Management

  • Company is restating 2014, 2015 results after investigation
  • CEO has been on extended medical leave since late December

Mike Pearson, chairman and chief executive officer of Valeant Pharmaceuticals International Inc.

Photographer: Scott Eells/Bloomberg

When Valeant Pharmaceuticals International Inc. holds a conference call to discuss unaudited fourth-quarter results on Monday, investors will get the first substantial update on the drugmaker since Chief Executive Officer Michael Pearson went on indefinite medical leave in late December.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.